Accessibility Menu
Imv logo

Imv(OTC) IMV

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-100%
5 Year-100%
1 Year+1,500%
1 Month+1,500%
N/A
Imv last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-28
Imv stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-19
1 month+1,500%USD 0.002026-07-28
3 month+1,500%USD 0.002026-05-29
Year to date+1,500%USD 0.002025-12-30
1 year+1,500%USD 0.002025-08-06
3 year-99.96%USD 0.052023-08-29
5 year-100%USD 16.502021-08-27
Since inception-100%USD 8.662012-05-25

Imv Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$36.62M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 9, 2023

IMV News

Coronavirus vaccine bottles

Why Several Coronavirus Vaccine Stocks Not Named Moderna Fell Today

Keith SpeightsJul 15, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Imv

IMV Inc. is a biopharmaceutical firm focused on immuno-oncology, currently in the clinical development stage. The company leverages its proprietary DPX immune-modulating platform to create a diverse range of treatments aimed at both solid tumors and blood cancers.

Products and Services
  • DPX immune-modulating platform for cancer therapies
  • Flagship therapeutic maveropepimut-S in Phase II studies
  • Pipeline includes DPX-SurMAGE and DPX-COVID-19
Growth Outlook
  • Advancing maveropepimut-S through Phase II for multiple cancers
  • DPX-SurMAGE in Phase I for bladder cancer
  • Strong focus on infectious diseases with DPX-COVID-19 and DPX-RSV
Financial Highlights
  • Recent quarterly net income of -$8.6 million
  • Cash and cash equivalents of $21.2 million as of Q4 2022
  • Current ratio of 2.93 indicates strong liquidity position
IMV Inc. is positioned in the biotechnology sector, focusing on innovative therapies for cancer and infectious diseases. The company's flagship product, maveropepimut-S, is currently undergoing clinical trials for various cancers, showcasing its commitment to advancing treatment options. The ongoing development of additional therapies, such as DPX-SurMAGE, highlights the potential for future growth. Financially, IMV Inc. has maintained a solid liquidity position, with a current ratio of 2.93, indicating the ability to cover short-term liabilities. Despite recent net losses, the company continues to invest in research and development, aiming to bring transformative therapies to market.
AI Generated • Aug 31, 2026

Industry

Biotechnology

Sector

Health Care

Employees

97

CEO

Andrew Hall

Website

www.imv-inc.com

Headquarters

Dartmouth, NS B3B 2C4, CA

IMV Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-495.17%

Return on Capital

-177.14%

Return on Assets

-117.99%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$39.49M

EBITDA

-$35.90M

Operating Cash Flow

-$33.40M

Capital Expenditure

-$1.07M

Free Cash Flow

-$34.47M

Cash & ST Invst.

$21.22M

Total Debt

$28.90M

Imv Performance Analysis

Imv annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
Imv sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-03-31N/A
Q22022-06-30N/A
Q32022-09-30N/A
Q42022-12-31N/A
Imv annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -4.93N/A
20222022-12-31USD -4.55-7.7%
Imv sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-03-3120.0%
Q22022-06-309.8%
Q32022-09-3024.4%
Q42022-12-31-14.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2022YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

63

N/A

Net Income

-$8.59M

+29.6%

EBITDA

-$8.34M

+24.5%

Quarterly Fundamentals

Name
Q4 2022YOY CHG

Total Cash

$21.22M

-45.0%

Total Debt

$28.90M

+47.0%

Accounts Receivable

$1.93M

+10.8%

Inventory

$0.00

N/A

Long Term Debt

$28.53M

+47.7%

Short Term Debt

$367.00K

+8.6%

Return on Assets

-1.18%

N/A

Return on Invested Capital

-1.80%

N/A

Free Cash Flow

-$6.51M

+19.3%

Operating Cash Flow

-$6.30M

+15.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
APGNApexigen, Inc.
$0.39+8.48%
EPIXESSA Pharma Inc.
$0.20-1.85%
TSBXTurnstone Biologics Corp.
$0.36+0.00%
TNFATNF Pharmaceuticals, Inc.
$5.20+48.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$219.72-0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.36-0.06%
INTCIntel
$88.83-0.01%
BIAFbioAffinity Technologies
$6.37+0.40%

Questions About IMV

What is the current price of Imv?

Imv is trading at N/A per share.

What is the 52-week range for Imv?

Over the past 52 weeks, Imv has traded between N/A and N/A.

How much debt does Imv have?

As of the most recent reporting period, Imv reported total debt of $28.90M.

How much cash does Imv have on hand?

Imv reported $21.22M in cash and cash equivalents in its most recent financial results.

What is Imv’s dividend yield?

Imv does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services